

Title	Association between hypertensive disorders of pregnancy and the risk of asthma, eczema and allergies in offspring: A systematic review and meta-analysis
Authors	Conlan, Nicola;Maher, Gillian M.;Al Khalaf, Sukainah;McCarthy, Fergus P.;Khashan, Ali S.
Publication date	2020-10-09
Original Citation	Conlan, N., Maher, G. M., Al Khalaf, S. Y., McCarthy, F. P. and Khashan, A. S. (2020) 'Association between hypertensive disorders of pregnancy and the risk of asthma, eczema and allergies in offspring: A systematic review and meta-analysis', Clinical and Experimental Allergy. doi: 10.1111/cea.13754
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1111/cea.13754
Rights	© 2020, John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Conlan, N., Maher, G. M., Al Khalaf, S. Y., McCarthy, F. P. and Khashan, A. S. (2020) 'Association between hypertensive disorders of pregnancy and the risk of asthma, eczema and allergies in offspring: A systematic review and meta-analysis', Clinical and Experimental Allergy, doi: 10.1111/cea.13754, which has been published in final form at https://doi.org/10.1111/cea.13754 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Download date	2025-08-28 19:10:13
Item downloaded from	https://hdl.handle.net/10468/10773



University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

1

2 DR GILLIAN MAHER (Orcid ID : 0000-0002-6722-0484)

3

4

5 Article type : Systematic reviews and Meta-analysis

6

7

8 **Association between Hypertensive Disorders of Pregnancy and the Risk of**
9 **Asthma, Eczema and Allergies in Offspring: A Systematic Review and Meta-**
10 **analysis**

11 Nicola Conlan¹ MPH, Gillian M. Maher^{#1,2} PhD, Sukainah Y. Al Khalaf^{1,2} MPH, Fergus P.
12 McCarthy^{2,3} PhD, Ali S. Khashan^{1,2} PhD

13

14 **Short title:** Hypertensive disorders of pregnancy and atopic disorders.

15

16 **Word count:** 4,056

17 **Table count:** 1

18 **Figure count:** 6

19

20 ¹School of Public Health, Western Gateway Building, University College Cork, Cork, Ireland.

21 ²INFANT Research Centre, University College Cork, Cork Ireland.

22 ³Department of Obstetrics and Gynaecology, University College Cork, Cork, Ireland

23

24 **Author contribution statement**

25 NC, ASK and GMM were involved in the planning of the study. NC, SAK and GMM were
26 involved in the search, selection and quality appraisal of included studies. NC and GMM
27 performed the analysis, and drafted the manuscript. ASK, FPM and GMM were involved in the
28 interpretation of results. All authors provided critical revision of the manuscript for important
29 intellectual content.

This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process, which may lead to
differences between this version and the [Version of Record](#). Please cite this article as [doi:](#)
[10.1111/CEA.13754](#)

This article is protected by copyright. All rights reserved

30

31

32

33 **#Corresponding Author:**

34 Dr. Gillian M. Maher

35 School of Public Health, 4th floor, Western Gateway Building, Western Road, University College

36 Cork, Cork, Ireland.

37 Telephone: +353(0)214205523

38 Email: gillian.maher@ucc.ie

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 **Abstract**

59 **Objective:** Conduct a systematic review and meta-analysis examining the association between
60 hypertensive disorders of pregnancy (HDP) and risk of asthma, eczema, food allergies and allergic
61 rhinitis in the offspring.

Design: A systematic review and random effects meta-analyses were used to synthesise the published literature. PRISMA guidelines were followed throughout. Two independent reviewers carried out data extraction and quality assessment of included studies. Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess certainty of findings.

Data Sources: A systematic search of PubMed, Embase, Web of Science and CINAHL was performed from inception of databases-April 21, 2020, supplemented by hand-searching reference lists of included articles.

Eligibility Criteria: Two reviewers independently reviewed titles, abstracts, and full-text articles. English-language, cohort, case-control and cross-sectional published studies examining the association between HDP (primary exposure: preeclampsia; secondary exposures: all other HDP) and asthma, eczema, food allergies and allergic rhinitis were included.

Results: Of the 2,833 studies retrieved, 14 studies met inclusion criteria. Of these, 11 studies reported evidence of association between HDP and atopic disorders. Thirteen studies reported estimates for asthma. Seven of these included adjusted estimates (including 3,645,773 participants) for a preeclampsia-asthma relationship resulting in a pooled odds ratio (OR) of 1.14 (95% CI: 1.04, 1.26) ($I^2=62\%$). However, this OR was reduced to 1.08 (95% CI: (0.78, 1.48) when the large registry based cohort studies were excluded, and only studies using parent-reported measures to determine a diagnosis of asthma were included. Four studies included adjusted estimates (including 254,998 participants) for other HDP and asthma (pooled OR: 1.02, 95% CI: 0.96, 1.09) ($I^2=0\%$). Two studies provided adjusted estimates (including 1,699,663 participants) for a preeclampsia-eczema relationship (pooled OR: 1.06, 95% CI: 0.98, 1.14) ($I^2=0\%$). One study including preeclampsia-food allergies was identified (OR: 1.28, 95% CI: 1.11, 1.46). Three studies examined a HDP (including preeclampsia) and allergic rhinitis relationship, with effect estimates ranging from 1.14 to 2.10. Studies were classified as low or low-moderate risk of bias, while GRADE certainty of findings were low to very low.

Conclusions: While preeclampsia was associated with a possible increased risk of asthma in offspring, there was no evidence for a relationship between other HDP and asthma. There is a lack of published literature examining the association between HDP and eczema, food allergy and allergic rhinitis. Further primary research is warranted to gain a better understanding of the association between HDP and the risk of childhood atopic disease.

Systematic review registration: Review protocol in appendix.

94 Introduction

95 Hypertensive disorders of pregnancy (HDP) are estimated to affect up to 10% of all pregnancies,
96 and are a recognised risk factor for maternal and prenatal morbidity and mortality⁽¹⁻³⁾. The
97 International Society for the Study of Hypertension in Pregnancy (ISSHP) categorises HDP as:
98 “chronic hypertension”, “white-coat hypertension”, “masked hypertension”, “gestational
99 hypertension”, and “preeclampsia” (*de novo*/superimposed on chronic hypertension⁽⁴⁾.
100 Hypertensive disorders of pregnancy are associated with maternal inflammation, oxidative stress
101 and disruption of blood flow to the placenta, all of which can impact fetal development⁽⁵⁾.
102 It is well established that pregnancy and early childhood are critical time periods for the
103 development of airways and the immune system, and genetic and environmental factors play
104 important roles in determining the development of atopic disorders in offspring⁽⁶⁻⁸⁾. Childhood
105 atopic disorders include asthma, eczema (also known as atopic dermatitis), food allergies and
106 allergic rhinitis, and are characterised by the development of an allergen-specific T helper type 2
107 (Th₂) response which often (but not always) includes the development of specific immunoglobulin
108 (IgE) targeted against the allergen⁽⁹⁾. The presence of these specific antibodies is detected using a
109 skin prick test or a blood test⁽⁸⁾.
110 Previous epidemiological research has indicated an association between HDP and atopic disorders
111 in offspring^(10, 11). For example, a population-based registry cohort with data on over 1.5 million
112 people suggested an association between preeclampsia and asthma after controlling for several
113 potential confounders⁽¹⁰⁾. However, results are conflicting as some relatively smaller studies do not
114 suggest an association^(12, 13). Furthermore, all studies on this topic were original studies, with no
115 systematic review conducted, to date.
116 Given that HDP are among the most common adverse prenatal conditions⁽³⁾, and the lack of
117 general consensus on this topic, collating existing evidence examining a HDP-atopic disorder
118 association is timely. Therefore, the aim of this study was to synthesise the available published
119 literature on the relationship between HDP and atopic disorders in the offspring in the form of a
120 systematic review and meta-analysis.

121 **Methods**

122 The systematic review was based on the following requirements:

123 **Population:** Pregnant women and their children

124 **Intervention/Exposure:** HDP (primary exposure: preeclampsia; secondary exposures: other
125 HDP)

126 **Comparison:** No preeclampsia/no HDP

127 **Outcomes:** Atopic disorders (outcome 1: asthma; outcome 2: eczema; outcome 3: food allergies;
128 outcome 4: allergic rhinitis)

129

130 **Data Sources and Search Strategy**

131 Based on a pre-prepared protocol (**Appendix 1**), and in accordance with the Preferred Reporting
132 Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines⁽¹⁴⁾, two reviewers (NC
133 and GMM) conducted a systematic literature search of four electronic databases: PubMed,
134 Embase, Web of Science and CINAHL, from inception through to April 21, 2020.

135 Search terms associated with HDP and asthma, eczema, food allergy and allergic rhinitis were
136 combined according to the principles of Boolean Logic (AND/OR/NOT) and using Medical
137 Subject Headings (MeSH). For example, (“Pre-eclampsia” OR “hypertensive disorders of
138 pregnancy”) AND (“asthma” OR “eczema” OR “food allergy” OR “allergic rhinitis”). The full
139 search strategy is included in Appendix 2. Results were limited to human studies, published in the
140 English language. No restrictions were placed on publication date, location of study or age of
141 participants. Searches of the electronic databases were supplemented by hand-searching the
142 reference lists of included studies for further potentially eligible studies, and contact with authors
143 was made when a conference proceeding only was located to identify if the relevant full-text paper
144 had been published. A post-hoc search of PubMed was also conducted adding the keywords
145 “bronchial spasm” OR “bronchial hyperreactivity” OR “respiratory hypersensitivity” to the search
146 strategy.

147

148 **Study Selection**

149 Titles and abstracts of studies retrieved from each database search were stored and managed in
150 Endnote reference manager©. Two review authors (NC, GMM) independently reviewed the titles
151 and abstracts of all studies, removing duplicates and obtaining full texts where necessary. Where

consensus on eligibility could not be achieved, a third review author (ASK) was involved in the discussion. Eligibility criteria for inclusion in the systematic review included:

- English language cohort, case-control or cross-sectional published studies where a HDP diagnosis was reported, and the outcome of interest was a childhood atopic disorder (asthma, eczema, food allergy and/or allergic rhinitis).
- Where the outcome of interest was asthma, this must be clearly defined (i.e. not wheezing).
- Peer-reviewed, epidemiological studies containing original data only.
- Examining the association between HDP and atopic disease in the offspring was part of the main objective of the study.
- Diagnosis of HDP could be confirmed through self-reporting (following doctor diagnosis) and/or medical records.
- Diagnosis of asthma, eczema, food allergies and allergic rhinitis could be confirmed through maternal-reporting/self-reporting (following doctor diagnosis) and/or medical records and/or clinical diagnosis and/or skin prick/blood test.
- Among studies conducted on the same population with overlapping time-periods, we chose the study covering the longest time-period for inclusion in the meta-analysis to avoid using the same population more than once.
- Conference abstracts were excluded.

Data Extraction

Two reviewers (NC, SAK) independently extracted data from all studies deemed eligible for inclusion, using a standardized data collection form. The extracted data included: the first author, publication year, data source, study design, region, study period, sample size, how both exposure and outcome were diagnosed, any confounders adjusted for (if any), matching factors (if any) and the overall result. Any discrepancies were resolved by consensus with a third reviewer (GMM). Authors of six studies were contacted to provide crude estimates and 95% confidence intervals (or raw data to allow us to compute effect estimates). A reply was received from four authors, of which, three could provide us with the additional information.

Bias and Quality Assessment

182 A funnel plot was used to visually assess the presence of publication bias for preeclampsia-asthma
183 studies only. Quality assessment of included studies was carried out by two reviewers (NC, SAK)
184 independently using an appropriate quality assessment tool described by McDonald et al.⁽¹⁵⁾, while
185 any discrepancies were resolved by a third reviewer (GMM) if necessary. The bias classification
186 tool assesses the six most common types of bias associated with observational studies. For each
187 eligible study, selection bias, exposure bias, outcome bias, confounding bias, analytic bias and
188 attrition bias were rated as minimal, low, moderate or high. An overall likelihood of bias based on
189 the total of the six types of bias was then reported. For example, risk of attrition bias was deemed
190 minimal if there was “none or <10% attrition, and reasons for loss of follow up [were] explained”,
191 while conversely risk of attrition bias was deemed as high if there was “>20% attrition, and
192 reasons for loss of follow up [was] not explained”. The Grading of Recommendations Assessment,
193 Development, and Evaluation (GRADE) approach was used to rate the certainty of findings. In the
194 GRADE approach, observational studies start as low-quality evidence. Five factors (risk of bias,
195 imprecision, inconsistency, indirectness, and publication bias) may lead to rating down the quality
196 of evidence and three factors (large effect, dose response, and if residual confounding is likely to
197 decrease rather than increase the magnitude of effect) may lead to rating up⁽¹⁶⁾.

198

199 **Statistical Analysis**

200 Where data permitted, Review Manager 5.3 was used to conduct meta-analyses. Using the generic
201 inverse variance method, the overall pooled estimate between preeclampsia and asthma was
202 calculated. The studies that adjusted for potential confounders during the analysis stage were
203 referred to as adjusted estimates. Crude estimates and adjusted estimates were analysed separately.
204 The overall pooled estimate between other HDP and asthma was also calculated using the generic
205 inverse variance method (with both crude and adjusted estimates analysed separately). Similarly,
206 the overall pooled estimate between preeclampsia and eczema was also calculated using the same
207 method (adjusted estimates only due to lack of data).

208 A random-effects model was used to calculate pooled odds ratios with 95% confidence intervals.
209 The random-effects model was selected to allow for differences in the ‘exposure effect’ from
210 study to study⁽¹⁷⁾. Forest plots were used to present the results. Heterogeneity was measured using
211 the I^2 , and was categorized as: 0-40% - might not be important; 30-60% - may represent moderate
212 heterogeneity; 50-90% - may represent substantial heterogeneity and 75-100% indicating

considerable heterogeneity, according to the Cochrane Handbook criteria⁽¹⁸⁾. Where data did not allow for meta-analyses to be conducted, a narrative synthesis was conducted to present results. *Subgroup/sensitivity analysis:* Subgroup/sensitivity analyses according to study design and location were decided *a priori*. *Post hoc sensitivity analyses:* Among asthma studies, three population-based registry studies with overlapping time-periods were conducted in Denmark^(10, 19, 20), while this occurred among two eczema studies^(10, 20). Therefore, while the main analyses included Stockholm et al⁽¹⁰⁾ (as this study covered the longest time-period), we also conducted a sensitivity analysis including one Danish cohort study at a time. In order to determine if a wide range of follow-up (i.e from early childhood to >18 years) had an impact on findings, we conducted post-hoc sensitivity analyses excluding (adjusted) studies with follow-up over 18 years of age⁽²¹⁾. To explore clinical/methodological sources of heterogeneity among preeclampsia-asthma studies, we excluded the large registry based cohort studies, therefore examining a preeclampsia-asthma relationship among studies that used parent-reported measures to determine a diagnosis of asthma.

Results

Search Results

The initial search produced 2,833 results prior to the removal of duplicates. Once duplicates were removed, 1,978 studies remained. Following the screening of titles and abstracts, 38 full text

articles were reviewed. Twenty-six articles were excluded for reasons outlined in **Figure 1**, resulting in the identification of 11 eligible studies. Following review of the reference lists of each eligible study, three further eligible studies were identified. Therefore, a total of 14 unique studies were included in the systematic review; 13 of which included data on asthma, five on eczema, one on food allergies, and three on allergic rhinitis.

Characteristics of Eligible Studies

Of the 13 studies that included data on asthma, there were 12 cohort studies^(7, 10-13, 20-26) and one case-control study⁽¹⁹⁾. Range of follow-up was between age <1 year and 13 years for the majority of studies^(7, 10, 12, 13, 22-26), while four studies followed participants up to adulthood (up to 27 years)^(11, 19-21). The average sample size among asthma studies was 537,198, with a minimum of 806⁽²³⁾ and a maximum of 1,698,638 participants⁽¹⁰⁾.

Of the five studies that include data on eczema, four were cohort studies^(10, 20, 22, 26) and one was cross-sectional with a retrospective cohort analysis⁽²⁷⁾. Range of follow-up was between age 3 years and 14 years for four studies^(10, 22, 26, 27), while one study followed participants up to 27 years⁽²⁰⁾. The average sample size was 654,718, with a minimum of 1,025⁽²²⁾ and a maximum of 1,698,638⁽¹⁰⁾.

One cohort study examined food allergies (n=1,698,638) up to seven years of age⁽¹⁰⁾, and three cohort studies examined allergic rhinitis (age ranges 3-14 years)^(10, 21, 22) with an average sample size of 1,702,986, a minimum of 1,025⁽²²⁾ and a maximum of 1,698,638⁽¹⁰⁾.

Ascertainment of HDP was determined using medical records in 11 studies^(7, 10-12, 19, 20, 22-26), measured directly in one study⁽¹³⁾ and was self-reported in two studies^(21, 27). Asthma diagnosis was determined using medical records in eight studies^(7, 10-12, 19, 20, 24, 26), while parental reporting was used in five studies^(13, 21-23, 25). A diagnosis of eczema was determined using medical records in three studies^(10, 20, 26), and parental reporting in two studies^(22, 27). Food allergy data was obtained from the Danish National Patient Register⁽¹⁰⁾, while data on allergic rhinitis was parental reported in two studies^(21, 22), and obtained from the Danish National Patient Register in one study⁽¹⁰⁾.

The confounders that were adjusted for included, amongst others: offspring gender, mode of delivery, gestational age, birthweight, parity, maternal age, smoking during pregnancy, maternal body mass index, maternal asthma, maternal education and allergen exposure. A summary of the eligible studies (including a full list of confounding factors) examining the association between HDP and asthma, eczema, food allergy and allergic rhinitis can be found in Appendices 3-6.

278 **Meta-Analysis Results**

279 *Asthma*: Thirteen studies investigating the association between HDP and asthma were identified^{(7,}
 280 ^{10-13, 19-26)}. Of these, 11 studies reported crude estimates^(7, 10-12, 19, 21-26), and 11 studies reported
 281 adjusted estimates^(7, 10, 12, 13, 19-25). Effect estimates ranged from 1.03-1.89 among the 11 studies
 282 reporting crude estimates, and from 0.80-1.34 among the 11 studies reporting adjusted estimates.

283 Eight studies (conducted on different populations without overlapping time-periods) included
 284 crude estimates for a preeclampsia-asthma relationship^(7, 10, 11, 22-26), while seven studies included
 285 adjusted estimates on preeclampsia-asthma^(7, 10, 13, 22-25). Crude pooled estimates (including
 286 3,919,377 participants) for preeclampsia resulted in an odds ratio (OR) of 1.22 (95% CI: 1.12,
 287 1.33) ($I^2=69\%$) (**Figure 2**). Adjusted estimates (including 3,645,773 participants) reduced the
 288 preeclampsia-asthma OR to 1.14 (95% CI: 1.04, 1.26) ($I^2=62\%$) (**Figure 3**).

289 Three studies included crudes estimates for other HPD-asthma^(12, 21, 25), while four studies included
 290 adjusted estimates^(12, 13, 21, 25). The crude pooled result (including 250,104 participants) for other
 291 HDP-asthma was 1.09 (95% CI: 1.02, 1.16) ($I^2=0\%$) (**Figure 4**), while the adjusted pooled result
 292 (including 254,998 participants) was 1.02 (0.96, 1.09) ($I^2=0\%$) (**Figure 5**).

293 *Eczema*: Five studies were identified that investigated the association between all HDP and
 294 eczema (atopic dermatitis) with effect estimates ranging from 0.96-1.14 among studies providing
 295 crude estimates, and from 0.90-1.84 among studies providing adjusted estimates^(10, 20, 22, 26, 27).

296 Two studies (conducted on different populations without overlapping time-periods) provided
 297 adjusted estimates (including 1,699,663 participants) for the association between preeclampsia and
 298 eczema^(10, 22) resulting in a pooled OR of 1.06 (95% CI: 0.98, 1.14) ($I^2=0\%$) (**Figure 6**). One
 299 Danish based study⁽²⁰⁾ (n=1,545,443) could not be included in the meta-analysis as it was
 300 conducted on a similar population with overlapping time-periods to Stockholm et al⁽¹⁰⁾: 1.04, (95%
 301 CI: 0.79, 1.38). One study provided a crude estimate only (n=24,690) for the relationship between
 302 eclampsia and eczema: 0.96, (95% CI: 0.73, 1.27)⁽²⁶⁾. Finally, one study provided an adjusted
 303 estimate only (n=3,794) for the relationship between other HDP and eczema: 1.08, (95% CI: 0.71,
 304 1.64)⁽²⁷⁾.

305 *Subgroup/sensitivity analysis:*

306 Study design: All seven cohort studies included in the meta-analysis^(7, 10, 13, 22-25) (with adjusted
 307 estimates) examining a preeclampsia-asthma association were cohort studies. All four studies
 308 (with adjusted estimates) examining other HDP-asthma were cohort studies^(12, 13, 21, 25). Similarly,

both studies (with adjusted estimates) examining a preeclampsia-eczema relationship were cohort studies^(10, 22).

Location: Six adjusted preeclampsia-asthma studies were conducted in Europe^(7, 10, 13, 22, 24, 25) (pooled OR: 1.14, 95% CI: 1.03, 1.26), while one adjusted preeclampsia study was conducted in the United States⁽²³⁾ (OR: 1.21, 95% CI: 0.51, 2.87). Three adjusted studies examining other HDP-asthma were conducted in Europe^(13, 21, 25) (pooled OR: 1.04, 95% CI: 0.88, 1.23), while one study was conducted in Australia⁽¹²⁾ (OR: 1.02, 95% CI: 0.95, 1.10). Both studies (with adjusted estimates) examining a preeclampsia-eczema relationship were conducted in Europe^(10, 22) (Table 1).

Post hoc sensitivity analysis: Including one Danish cohort study with overlapping time-periods at a time did not materially change results. Adjusted OR for preeclampsia-asthma including Stockholm et al⁽¹⁰⁾: 1.14 (95% CI: 1.04, 1.26 - $I^2=62\%$), including Wu et al⁽²⁰⁾: 1.15 (95% CI: 1.03, 1.29 - $I^2=38\%$), and including Liu et al⁽¹⁹⁾: 1.19 (95% CI: 1.12, 1.26 - $I^2=31\%$). Adjusted OR for preeclampsia-eczema including Stockholm et al⁽¹⁰⁾: 1.06 (95% CI: 0.98, 1.14 - $I^2=0\%$), and including Wu et al⁽²⁰⁾: 1.01 (95% CI: 0.80, 1.27 - $I^2=0\%$).

Excluding the other HDP-asthma study with follow-up over 18 years of age did not materially change results⁽²¹⁾: (other HDP-asthma: OR 1.02, 95% CI: 0.96, 1.09 - ($I^2=0\%$)). All other studies included in the meta-analyses were followed-up for <18 years (preeclampsia-asthma: OR 1.14, 95% CI: 1.04, 1.26 - ($I^2=62\%$)), (preeclampsia-eczema: OR 1.06, 95% CI: 0.98, 1.14 - ($I^2=0\%$)) (see Table 1 for a summary of results).

Excluding the large registry based cohort studies among preeclampsia-asthma studies^(7, 10, 24) (and therefore examining a preeclampsia-asthma relationship among studies that used parent-reported measures to determine a diagnosis of asthma^(13, 22, 23, 25)) resulted in an OR of 1.08 (95% CI: 0.78, 1.48) (Table 1 and Appendix 7, eFigure 1).

333

334

335

336 **Narrative Synthesis Results**

337 *Food allergies and allergic rhinitis:* As the systematic search identified only one study exploring
 338 the association between HDP and food allergies⁽¹⁰⁾ and three studies exploring the association
 339 between HDP and allergic rhinitis^(10, 21, 22), meta-analyses were not conducted for these outcomes.
 340 The one identified study that investigated food allergies⁽¹⁰⁾ reported a positive association between

preeclampsia and food allergies in offspring: adjusted estimate 1.21 (95% CI: 1.05, 1.39). This same study⁽¹⁰⁾ also examined allergic rhinitis and reported a positive association between preeclampsia and allergic rhinitis: adjusted estimate 1.14 (95% CI, 1.05, 1.24). A second study which examined preeclampsia-allergic rhinitis (stratified by mild/moderate and severe preeclampsia)⁽²²⁾ reported an adjusted OR of 1.21 (95% CI: 0.70, 2.07) for mild/moderate preeclampsia and 2.10 (95% CI: 0.86, 5.11) for severe preeclampsia. Finally, one study examined other HDP-allergic rhinitis⁽²¹⁾, resulting in an adjusted OR of 1.42 (95% CI: 0.84, 2.40). A summary of these studies can be found in Appendices 5 and 6.

Bias and Heterogeneity

Visual assessment of the funnel plot did not indicate presence of publication bias (Appendix 8, eFigure 2). There was substantial heterogeneity among preeclampsia-asthma studies ($I^2=62\%$) and low heterogeneity among studies that include other HDP and asthma ($I^2=0\%$) based on adjusted estimates. Similarly, there was low heterogeneity among preeclampsia-eczema studies ($I^2=0\%$). Heterogeneity between preeclampsia-asthma studies was possibly due to the larger registry based cohort studies as heterogeneity was reduced to 0% these were excluded^(7, 10, 24) (Appendix 7, eFigure 1). In addition to this, it is possible that varying methods of exposure and outcomes measures (as outlined in Appendix 3) may have resulted in clinical/methodological sources of heterogeneity. For example, the I^2 among preeclampsia-asthma studies that use parent-reported measures^(13, 22, 23, 25) to determine a diagnosis of asthma was 0% (Appendix 7, eFigure 1). The majority of studies were classified as 'low' or 'low-moderate' risk of bias (Appendices 9-12). GRADE certainty of findings were low to very low (Appendix 13).

373

374

375

376

377

378

379

380

381

382

383

384

385 Discussion

386 The objective of this systematic review and meta-analysis was to investigate the association
387 between HDP and asthma, eczema, food allergy and allergic rhinitis in offspring, yielding three
388 principal findings.

389 First, the adjusted pooled estimate suggested that preeclampsia was associated with a 14%
390 increase in the likelihood of asthma compared to those unexposed to preeclampsia (OR: 1.14, 95%
391 CI: (1.04, 1.26), while the adjusted pooled estimate examining the other HDP-asthma relationship
392 produced an OR of 1.02 (95% CI: 0.96, 1.09). It was proposed by Stokholm et al⁽¹⁰⁾ that the *in*
393 *utero* exposure to excessive inflammation associated with preeclampsia could be leading to the
394 preeclampsia-asthma association, proposing that the skewed distribution of T cells in preeclamptic
395 women could increase IgE levels in offspring, thus increasing the risk of asthma⁽¹⁰⁾. This may
396 partly explain why an association was observed between preeclampsia-asthma, and not other
397 HDP-asthma. Furthermore, fetal growth restriction, which is now included in the definition of
398 preeclampsia, as per ISSHP guidelines⁽⁴⁾, may also play a role and has been linked to an increased
399 risk of asthma in previous literature⁽²⁸⁾.

400 Second, the adjusted pooled estimate examining a preeclampsia-eczema relationship produced an
401 OR of 1.06 (95% CI: 0.98, 1.14). However, only two studies (conducted on different populations
402 without overlapping time-periods) were identified for inclusion in the meta-analysis^(10, 20, 22),
403 highlighting the paucity of research measuring this association.

404 Third, there was a dearth of literature supporting an association between HDP and food allergies
405 and HDP and allergic rhinitis. Only one publication was identified exploring the relationship
406 between preeclampsia and food allergy⁽¹⁰⁾. This study reported an OR of 1.21 (95% CI: 1.05, 1.39)
407 and proposed that the risk of food allergy increased as the duration of exposure to preeclampsia
408 was extended⁽¹⁰⁾. Given the increasing prevalence of childhood onset food allergies⁽²⁹⁾, it is timely
409 that further research in this area is initiated. Finally, only three studies were identified exploring
410 the association between HDP and allergic rhinitis^(10, 21, 22). All three studies reported a positive
411 association between HDP and allergic rhinitis (with effect estimates ranging from 1.14 to 2.10,
412 and results of two of these studies spanning the null value^(21, 22)) citing the involvement of an
413 inflammatory response involving a skewed distribution of T cells in the preeclamptic women as
414 the potential biological mechanism^(10, 22). However, further research is warranted to further
415 investigate if such an association exists, and if so, what biological mechanisms are involved.

416

417 **Strengths and Limitations**

418 This systematic review contains several strengths. A thorough search of four relevant electronic
419 databases was conducted, supplemented by manually reviewing the reference lists of the eligible
420 studies for further suitable studies. Each process of the systematic review was carried out by two
421 independent reviewers and PRISMA guidelines were followed throughout⁽¹⁴⁾. Finally, we
422 attempted to contact several authors for further information to ensure data contained within the
423 meta-analysis was as comprehensive as possible.

424 However, this systematic review also contains several limitations. We included English-language
425 studies only, potentially overlooking relevant, non-English language studies. We only included
426 published, full-text articles, therefore excluding data from grey literature or conference
427 proceedings. Furthermore, as the full search strategy may have been lacking in keywords such as
428 “bronchial spasm” OR “bronchial hyperreactivity” OR “respiratory hypersensitivity”, we
429 conducted a post-hoc search of PubMed, adding these words to the search strategy. While this
430 increased the number of hits retrieved, no new relevant studies were identified in the process. The
431 small number of published studies also limited this review. While visual assessment of the funnel
432 plot of preeclampsia-asthma studies did not indicate the presence of publication bias, it was not
433 feasible to generate a funnel plot for other HDP-asthma or preeclampsia-eczema due to the limited
434 number of published studies. In addition, it is important to note that the reported positive
435 association between preeclampsia and asthma should be considered with caution given that only

seven studies were included in the meta-analysis, and a high degree of heterogeneity was reported ($I^2=62\%$). Studies included in this systematic review also contain some limitations. For example, while the majority of studies were classified as 'low' or 'low-moderate' risk of bias, GRADE certainty of findings were low to very low, indicating that the true effect may be different from the estimated effect⁽¹⁶⁾. Furthermore, while the majority of studies attempted to control for confounding in their analysis phase, residual or unmeasured confounding cannot be ruled out in observational studies⁽³⁰⁾. Selection of potential confounders varied in each study and were identified from existing literature or the research team's knowledge of the subject, however only one study appears to have aided the selection of confounders using a directed acyclic graph⁽²⁵⁾. It is important to acknowledge that some of the factors controlled for, as potential confounders, could in fact be potential mediators of the HDP-atopic disorder association. For example, eight studies controlled for a combination of mode of delivery, gestational age and birthweight, which may have biased results towards the null and thus, should be interpreted with caution^(10-12, 20-23, 25, 31). All studies with adjusted estimates considered maternal age and infant sex as potential confounders. Seven of the 13 eligible asthma studies recognised the potential confounding role of maternal asthma^(7, 10, 19, 21, 22, 24, 25), while maternal smoking was also identified as a potential confounder in seven studies^(7, 10, 13, 19, 21, 22, 25), with the majority of these studies attenuating towards the null when adjusted^(7, 10, 13, 19, 21, 22). However, exposure to certain environmental factors during pregnancy, which may be associated with asthma development could also be considered as potential confounders. Such factors include exposure to traffic pollution, antibiotic use and viral infection⁽³²⁾. The former was not considered in any of the included studies, while antibiotic use was adjusted for in two studies^(10, 21), and viral infection was considered as a confounder in only one study⁽²⁴⁾. Additionally, few studies included data on severity of preeclampsia or other HDP^(11, 20, 22), and were limited by small sample sizes (as fewer than ten cases of asthma were exposed to severe preeclampsia in one study)⁽²²⁾, and residual confounding (as confounders were not adjusted for when examining preeclampsia-asthma specifically in a separate study)⁽¹¹⁾. Finally, the role of antihypertensive medication used during pregnancy should be explored in order to determine its potential impact on the development of atopic disorders in offspring⁽³³⁾.

Conclusion

468 This systematic review and meta-analysis indicates that preeclampsia may be associated with an
469 increased risk of asthma in the offspring, while there was no evidence for a relationship between
470 other HDP and asthma. Further research is warranted to validate these findings and to determine if
471 the observed relationship is causal. Insufficient published literature was available to substantiate
472 whether an association exists between HDP and eczema, food allergy and/or allergic rhinitis.
473 Further primary research is needed to explore these associations.

474

475 **Appendices**

476 Refer to web version for appendices.

477

478 **Conflict of Interest:** No conflicts of interest, including financial interest.

479

480 **Acknowledgments**

481 **Funding:** This publication has emanated from research conducted with the financial support of the
482 Health Research Board (HRB), Ireland, (SDAP2019/ 6359).

483 **References**

- 484 1. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A-B, Daniels J, et al. Global causes of maternal death:
485 a WHO systematic analysis. The Lancet Global Health. 2014;2(6):e323-e33.
- 486 2. Vogel JP, Souza JP, Mori R, Morisaki N, Lumbiganon P, Laopaiboon M, et al. Maternal
487 complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on
488 Maternal and Newborn Health. BJOG : an international journal of obstetrics and gynaecology. 2014;121
489 Suppl 1:76-88.
- 490 3. Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk
491 factors, predictors and prognosis. Hypertens Res. 2017;40(3):213-20.
- 492 4. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive
493 disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international
494 practice. Pregnancy Hypertens. 2018;13:291-310.
- 495 5. Chaiworapongsa T, Chaemsaitong P, Yeo L, Romero R. Pre-eclampsia part 1: current
496 understanding of its pathophysiology. Nature reviews Nephrology. 2014;10(8):466-80.
- 497 6. Wegienka G, Zoratti E, Johnson CC. The role of the early-life environment in the development of
498 allergic disease. Immunology and allergy clinics of North America. 2015;35(1):1-17.

- 499 7. Magnus MC, Håberg SE, Magnus P, Engeland A, Nafstad P, Karlstad Ø, et al. Pre-eclampsia and
500 childhood asthma. *The European respiratory journal*. 2016;48(6):1622-30.
- 501 8. Gold MS, Kemp AS. Atopic disease in childhood. *Medical journal of Australia*. 2005;182(6):298-
502 304.
- 503 9. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. *Annals of allergy,*
504 *asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*.
505 2018;120(2):131-7.
- 506 10. Stokholm J, Sevelsted A, Anderson UD, Bisgaard H. Preeclampsia Associates with Asthma, Allergy,
507 and Eczema in Childhood. *American journal of respiratory and critical care medicine*. 2017;195(5):614-21.
- 508 11. Nahum Sacks K, Friger M, Shoham-Vardi I, Sergienko R, Landau D, Sheiner E. In utero exposure to
509 pre-eclampsia as an independent risk factor for long-term respiratory disease. *Pediatric pulmonology*.
510 2020;55(3):723-8.
- 511 12. Algert CS, Bowen JR, Lain SL, Allen HD, Vivian-Taylor JM, Roberts CL. Pregnancy exposures and risk
512 of childhood asthma admission in a population birth cohort. *Pediatric allergy and immunology : official*
513 *publication of the European Society of Pediatric Allergy and Immunology*. 2011;22(8):836-42.
- 514 13. Wilmink FA, den Dekker HT, de Jongste JC, Reiss IKM, Jaddoe VWV, Steegers EA, et al. Maternal
515 blood pressure and hypertensive disorders during pregnancy and childhood respiratory morbidity: the
516 Generation R Study. *The European respiratory journal*. 2018;52(5).
- 517 14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and
518 meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264-9.
- 519 15. McDonald SD, Han Z, Mulla S, Murphy KE, Beyene J, Ohlsson A. Preterm birth and low birth weight
520 among in vitro fertilization singletons: a systematic review and meta-analyses. *European Journal of*
521 *Obstetrics & Gynecology and Reproductive Biology*. 2009;146(2):138-48.
- 522 16. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—
523 GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology*. 2011;64(4):383-
524 94.
- 525 17. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ (Clinical*
526 *research ed)*. 2011;342:d549.
- 527 18. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane Handbook for*
528 *Systematic Reviews of Interventions version 6.0 (updated July 2019)*. Cochrane, 2019. [Available from:
529 www.training.cochrane.org/handbook.

- 530 19. Liu X, Olsen J, Agerbo E, Yuan W, Wu CS, Li J. Maternal preeclampsia and childhood asthma in the
531 offspring. *Pediatric allergy and immunology : official publication of the European Society of Pediatric*
532 *Allergy and Immunology*. 2015;26(2):181-5.
- 533 20. Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers
534 who had preeclampsia: a population-based cohort study. *American journal of obstetrics and gynecology*.
535 2009;201(3):269.e1-.e10.
- 536 21. Pesce G, Marchetti P, Calciano L, Pironi V, Ricci P, Marcon A. Fetal Exposure to Maternal
537 Pregnancy Complications and Respiratory Health in Childhood. *Pediatric, Allergy, Immunology, and*
538 *Pulmonology*. 2017;30(4):218-26.
- 539 22. Byberg KK, Ogland B, Eide GE, Oymar K. Birth after preeclamptic pregnancies: association with
540 allergic sensitization and allergic rhinoconjunctivitis in late childhood; a historically matched cohort study.
541 *BMC pediatrics*. 2014;14:101.
- 542 23. Mirzakhani H, Carey VJ, McElrath TF, Qiu W, Hollis BW, O'Connor GT, et al. Impact of Preeclampsia
543 on the Relationship between Maternal Asthma and Offspring Asthma. An Observation from the VDAART
544 Clinical Trial. *American journal of respiratory and critical care medicine*. 2019;199(1):32-42.
- 545 24. Nafstad P, Samuelsen SO, Irgens LM, Bjerkedal T. Pregnancy complications and the risk of asthma
546 among Norwegians born between 1967 and 1993. *European journal of epidemiology*. 2003;18(8):755-61.
- 547 25. Shaheen SO, Macdonald-Wallis C, Lawlor DA, Henderson AJ. Hypertensive disorders of pregnancy,
548 respiratory outcomes and atopy in childhood. *The European respiratory journal*. 2016;47(1):156-65.
- 549 26. McKeever TM, Lewis SA, Smith C, Hubbard R. The Importance of Prenatal Exposures on the
550 Development of Allergic Disease. *American journal of respiratory and critical care medicine*.
551 2002;166(6):827-32.
- 552 27. Pesce G, Marcon A, Marchetti P, Girardi P, de Marco R. Febrile and gynecological infections during
553 pregnancy are associated with a greater risk of childhood eczema. *Pediatric allergy and immunology :*
554 *official publication of the European Society of Pediatric Allergy and Immunology*. 2014;25(2):159-65.
- 555 28. Tedner SG, Örtqvist AK, Almqvist C. Fetal growth and risk of childhood asthma and allergic
556 disease. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical*
557 *Immunology*. 2012;42(10):1430-47.
- 558 29. Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn J, Fiocchi A, et al. A global survey of changing
559 patterns of food allergy burden in children. *The World Allergy Organization journal*. 2013;6(1):21.
- 560 30. Flanders WD, Klein M, Darrow LA, Strickland MJ, Sarnat SE, Sarnat JA, et al. A method for
561 detection of residual confounding in time-series and other observational studies. *Epidemiology*
562 (Cambridge, Mass). 2011;22(1):59-67.

- 563 31. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in
 564 epidemiologic studies. *Epidemiology (Cambridge, Mass)*. 2009;20(4):488-95.
- 565 32. Asher I, Pearce N. Global burden of asthma among children. *The international journal of*
 566 *tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and*
 567 *Lung Disease*. 2014;18(11):1269-78.
- 568 33. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital
 569 malformations and perinatal events among infants exposed to calcium channel and beta-blockers during
 570 pregnancy. *Pharmacoepidemiology and drug safety*. 2011;20(2):138-45.

571

572

573

574 Flowchart of Study Selection

575

576

577

578


579

580

581

582

583



582 **Figure 1** Flow diagram of studies selected for inclusion in the systematic review.

Forest Plots for Studies of the Association between Preeclampsia and Asthma




Figure 2 Forest Plot for the Association of Preeclampsia with Asthma (crude estimates).




Figure 3 Forest Plot for the Association of Preeclampsia with Asthma (adjusted estimates).

Forest Plots for Studies of the Association between other Hypertensive Disorders of Pregnancy (HDP) and Asthma




Figure 4 Forest Plot for the Association of other HDP with Asthma (crude estimates).




Figure 5 Forest Plot for the Association of other HDP with Asthma (adjusted estimates).

Forest Plot for Studies of the Association between Preeclampsia and Eczema




Figure 6 Forest Plot for the Association of Preeclampsia with Eczema (adjusted estimates)

Table 1: Meta-analyses for HDP-Asthma and HDP-Eczema					
Asthma	Number of studies	N	OR	95% CI	I²
Preeclampsia (crude)	8	3919377	1.22	(1.12, 1.33)	69%
Preeclampsia (adjusted)	7	3645773	1.14	(1.04, 1.26)	62%
Other HDP (crude)	3	250104	1.09	(1.02, 1.16)	0%
Other HDP (adjusted)	4	254998	1.02	(0.96, 1.09)	0%
<i>Study design^a</i>					
Cohort (preeclampsia)	7	3645773	1.14	(1.04, 1.26)	62%
Cohort (other HDP)	4	254998	1.02	(0.96, 1.09)	0%
<i>Location^a</i>					
Europe (preeclampsia)	6	3644967	1.14	(1.03, 1.26)	68%
United States (preeclampsia)	1	806	1.21	(0.51, 2.87)	NA
Europe (other HDP)	3	14487	1.04	(0.88, 1.23)	0%
Australia (other HDP)	1	240511	1.02	(0.95, 1.10)	NA
<i>Including one Danish cohort study at a time^a</i>					
Preeclampsia	7	3645773	1.14	(1.04, 1.26)	62%
Preeclampsia	7	3492578	1.15	(1.03, 1.29)	38%
Preeclampsia	7	3217867	1.19	(1.12, 1.26)	31%
<i>Excluding studies with >18 years of follow-up^a</i>					
Preeclampsia	7	3645773	1.14	(1.04, 1.26)	62%
Other HDP	3	252379	1.02	(0.96, 1.09)	0%
<i>Excluding the large registry based cohort studies^a</i>					
Preeclampsia	4	13699	1.08	(0.78, 1.48)	0%
Eczema	Number of studies	N	OR	95% CI	I²
Preeclampsia (adjusted)	2	1699663	1.06	(0.98, 1.14)	0%
<i>Study design^a</i>					
Cohort (preeclampsia)	2	1699663	1.06	(0.98, 1.14)	0%
<i>Location^a</i>					
Europe (preeclampsia)	2	1699663	1.06	(0.98, 1.14)	0%
<i>Including one Danish cohort study at a time^a</i>					
Preeclampsia	2	1699663	1.06	(0.98, 1.14)	0%
Preeclampsia	2	1546468	1.01	(0.80, 1.27)	0%
<i>Excluding studies with >18 years of follow-up^a</i>					
Preeclampsia	2	1699663	1.06	(0.98, 1.14)	0%
^a Includes all studies that adjusted for confounders in the analysis phase.					